Background
Methods
Study population
Study design and treatment randomization
Study end points
Preparation and administration of WJMSCs
F-18-FDG-PET and 99mTc-sestamibi SPECT examination
Two-dimensional echocardiogram examination
Statistical analyses
Results
Participant characteristics
Characteristic | Placebo | WJMSCs | P value |
---|---|---|---|
(n = 58) | (n = 58) | ||
Risk factor
| |||
Age (years) | 56.7±1.7 | 57.3±1.3 | 0.79 |
Men - number (%) | 51(87.9) | 55(94.8) | 0.18 |
Body-mass index (kg/m2) | 25.4±0.3 | 24.9±0.3 | 0.26 |
Diabetes mellitus - number (%) | 14(24.1) | 17(29.3) | 0.52 |
Hyperlipidemia - number (%) | 22(37.9) | 21(36.2) | 0.84 |
Hypertension - number (%) | 26(44.8) | 33(56.9) | 0.19 |
Smoking (current of former) -number (%) | 32(55.2) | 34(58.6) | 0.70 |
Family history of coronary heart disease - number (%) | 20(34.5) | 17(29.3) | 0.55 |
Coronary artery disease - number (%)
| 0.19 | ||
1-Vessel disease | 28(48.3) | 21(36.2) | |
2-Vessel disease | 16(27.6) | 14(24.1) | |
3-Vessel disease | 14(24.1) | 23(39.7) | |
Infarct treatment
| |||
Infarct-related artery - number (%) | 0.55 | ||
Left anterior descending artery | 31(53.4) | 29(50.0) | |
Left circumflex artery | 6(10.3) | 10(17.2) | |
Right coronary artery | 21(36.2) | 19(32.8) | |
PCI for additional stenoses in non-infarct-related vessels - number (%) | 10(17.2) | 15(25.9) | 0.25 |
Time from symptom onset to first reperfusion therapy-hour | |||
Mean | 7.3±0.5 | 7.2±0.5 | 0.81 |
Median | 6.3 | 7.3 | |
Drug-eluting stent - number (%) | 58(100) | 58(100) | 1 |
Gp II b/IIIa inhibitor during acute PCI - number (%) | 7(12.1) | 8(13.8) | 0.78 |
Intravenous catecholamines - number (%) | 3(5.2) | 4(6.9) | 0.69 |
Maximal creatine kinase (U/L) | 1899±273 | 1653±206 | 0.93 |
Maximal creatine kinase MB (U/L) | 192±21 | 170±17 | 0.42 |
Maximal troponin T (μg/L) | 18.2±3.1 | 24.7±4.1 | 0.61 |
TIMI flow grade
| |||
Before PCI - number (%) | 0.93 | ||
Grade 0 or 1 | 42(72.4) | 42(72.4) | |
Grade 2 | 8(13.8) | 7(12.1) | |
Grade 3 | 8(13.8) | 9(15.5) | |
After PCI - number (%) | 0.55 | ||
Grade 0 or 1 | 0(0) | 0(0) | |
Grade 2 | 1(1.7) | 2(3.4) | |
Grade 3 | 57(98.3) | 56(96.6) | |
Baseline quantitative measure of LV function
| |||
Global left ventricular ejection fraction (%) | |||
Mean | 51.1±1.0 | 52.0±0.9 | 0.51 |
Left venticular fractional shortening (%) | |||
Mean | 26.4±0.6 | 27.2±0.6 | 0.33 |
Wall motion score index (17-segment model) | |||
Mean | 1.28±0.03 | 1.29±0.02 | 0.62 |
End-systolic volume (ml) | |||
Mean | 64.6±2.8 | 63.3±2.7 | 0.68 |
End-diastolic volume (ml) | |||
Mean | 129.9±3.5 | 130.4±3.6 | 0.90 |
Cell therapy
| |||
Time from reperfusion to infusion of study therapy-days | |||
Mean | 6.3±0.1 | 6.1±0.1 | 0.25 |
Median | 6.5 | 6.0 | |
TIMI flow grade before study therapy | |||
Mean | 2.98±0.02 | 2.97±0.02 | 0.56 |
Median | 3 | 3 | |
TIMI flow grade after study therapy | |||
Mean | 2.98±0.02 | 2.97±0.02 | 0.56 |
Median | 3 | 3 | |
Current medication - number (%)
| |||
Aspirin and clopidogrel | 58(100) | 58(100) | 1 |
Beta-blocker | 48(82.8) | 42(72.4) | 0.18 |
ACE-inhibitors or angiotensin-receptor B | 43(74.1) | 42(72.4) | 0.83 |
Stains | 54(93.1) | 54(93.1) | 1 |
Adverse events (AEs)
Event | Placebo | WJMSCs | P value |
---|---|---|---|
Events during procedure
| (n=58) | (n=58) | |
Death | 0 | 0 | |
Obstruction of related-vessel | 0 | 0 | |
Severe arrhythmia | 0 | 0 | |
Events 6-mo follow-up (cumulative)
a
| (n=57) | (n=58) | |
Death | 1 | 0 | 0.49b |
Recurrence MI | 0 | 0 | |
Rehospitalization for heart failure | 0 | 1 | 1.0b |
Stent thrombosis | 0 | 0 | |
Revascularization | 0 | 1 | 1.0b |
Cerebral infarction | 0 | 0 | |
Arrhythmia | 0 | 0 | |
Immune system disorder | |||
Ectopic tissue formation | 0 | 1 | 1.0b |
Combined events
| |||
Death or MI | 1 | 0 | 0.49b |
Death, recurrence of MI, revascularization procedure | 1 | 1 | 1b |
Death, MI, or rehospitalization for heart failure | 1 | 1 | 1b |
Death, MI, stroke, rehospitalization for heart failure, severe arrhythmia | 1 | 1 | 1b |
Immune system disorder, ectopic tissue formation | 0 | 1 | 1b |
Events 12-mo follow-up (cumulative)
| |||
Death | 1 | 0 | 0.49b |
Recurrence MI | 0 | 0 | |
Rehospitalization for heart failure | 0 | 1 | 1.0b |
Stent thrombosis | 0 | 0 | |
Revascularization | 0 | 1 | 1.0b |
Cerebral infarction | 0 | 0 | |
Arrhythmia | 0 | 0 | |
Immune system disorder | 0 | 0 | |
Ectopic tissue formation | 1 | 1 | 1.0b |
Combined events
| |||
Death or MI | 1 | 0 | 0.49b |
Death, recurrence of MI, revascularization procedure | 1 | 1 | 1b |
Death, MI, or rehospitalization for heart failure | 1 | 1 | 1b |
Death, MI, stroke, rehospitalization for heart failure, severe arrhythmia | 1 | 1 | 1b |
Immune system disorder, ectopic tissue formation | 1 | 1 | 1b |
Events 18-mo follow-up (cumulative)
| |||
Death | 1 | 0 | 0.49b |
Recurrence MI | 0 | 0 | |
Rehospitalization for heart failure | 0 | 1 | 1.0b |
Stent thrombosis | 0 | 0 | |
Revascularization | 0 | 1 | 1.0b |
Cerebral infarction | 0 | 0 | |
Arrhythmia | 0 | 0 | |
Immune system disorder | 0 | 0 | |
Ectopic tissue formation | 1 | 1 | 1.0b |
Combined events
| |||
Death or MI | 1 | 0 | 0.49b |
Death, recurrence of MI, revascularization procedure | 1 | 1 | 1b |
Death, MI, or rehospitalization for heart failure | 1 | 1 | 1b |
Death, MI, stroke, rehospitalization for heart failure, severe arrhythmia | 1 | 1 | 1b |
Immune system disorder, ectopic tissue formation | 1 | 1 | 1b |
Blood index | Placebo | WJMSCs | P value |
---|---|---|---|
(number = 55) | (number = 57) | ||
CD3(%)
| |||
Baseline | 66.8±0.9 | 67.6±0.8 | 0.48 |
3 Days | 67.6±1.1 | 69.1±0.9 | 0.29 |
P value(baseline vs.3d) | 0.43 | 0.08 | |
1 Mo | 67.3±1.0 | 66.6±0.9 | 0.53 |
P value (baseline vs.1 mo) | 0.58 | 0.18 | |
4 Mo | 65.2±0.7 | 66.3±0.9 | 0.34 |
P value (baseline vs.6 mo) | 0.06 | 0.11 | |
12 Mo | 66.2±0.9 | 66.4±0.8 | 0.81 |
P value (baseline vs.12 mo) | 0.64 | 0.16 | |
18 Mo | 67.1±1.0 | 66.8±0.9 | 0.76 |
P value (baseline vs.18 mo) | 0.66 | 0.29 | |
CD4(%)
| |||
Baseline | 39.6±1.2 | 40.1±0.8 | 0.70 |
3 Days | 40.4±1.1 | 39.3±0.8 | 0.39 |
P value (baseline vs.3 d) | 0.37 | 0.24 | |
1 Mo | 38.2±1.0 | 37.1±0.7 | 0.34 |
P value (baseline vs.1 mo) | 0.09 | <0.0001 | |
4 Mo | 37.7±1.1 | 38.0±0.8 | 0.75 |
P value (baseline vs.6 mo) | 0.09 | 0.02 | |
12 Mo | 37.6±0.9 | 38.2±0.6 | 0.58 |
P value (baseline vs.12 mo) | 0.11 | 0.03 | |
18 Mo | 38.8±1.1 | 39.2±0.9 | 0.45 |
P value (baseline vs.18 mo) | 0.09 | 0.16 | |
CD8(%)
| |||
Baseline | 21.9±0.9 | 22.4±0.8 | 0.39 |
3 Days | 21.3±0.8 | 22.9±0.8 | 0.13 |
P value (baseline vs.3 d) | 0.36 | 0.16 | |
1 Mo | 21.5±0.5 | 22.8±0.7 | 0.14 |
P value (baseline vs.1 mo) | 0.63 | 0.47 | |
4 Mo | 21.5±0.7 | 21.8±0.7 | 0.78 |
P value (baseline vs.6 mo) | 0.66 | 0.32 | |
12 Mo | 23.2±0.4 | 22.2±0.6 | 0.16 |
P value (baseline vs.12 mo) | 0.12 | 0.80 | |
18 Mo | 22.4±0.7 | 23.6±0.9 | 0.21 |
P value (baseline vs.18 mo) | 0.56 | 0.71 | |
IgG(g/L)
| |||
Baseline | 11.1±0.3 | 10.7±0.3 | 0.42 |
3 Days | 11.3±0.3 | 11.0±0.2 | 0.34 |
P value (baseline vs.3d) | 0.41 | 0.39 | |
1 Mo | 11.5±0.4 | 10.9±0.4 | 0.13 |
P value (baseline vs.1 mo) | 0.10 | 0.63 | |
4 Mo | 10.9±0.4 | 10.3±0.4 | 0.48 |
P value (baseline vs.6 mo) | 0.74 | 0.36 | |
12 Mo | 11.8±0.3 | 11.3±0.4 | 0.31 |
P value (baseline vs.12 mo) | 0.09 | 0.13 | |
18 Mo | 11.6±0.5 | 11.1±0.5 | 0.18 |
P value (baseline vs.18 mo) | 0.11 | 0.64 | |
IgM(g/L)
| |||
Baseline | 1.10±0.10 | 1.07±0.08 | 0.80 |
3 Days | 1.15±0.09 | 1.05±0.07 | 0.38 |
P value (baseline vs.3d) | 0.24 | 0.67 | |
1 Mo | 1.24±0.11 | 1.23±0.10 | 0.69 |
P value (baseline vs.1 mo) | 0.28 | 0.15 | |
4 Mo | 1.17±0.10 | 1.05±0.08 | 0.35 |
P value (baseline vs.6 mo) | 0.50 | 0.69 | |
12 Mo | 1.14±0.06 | 1.15±0.05 | 0.55 |
P value (baseline vs.12 mo) | 0.66 | 0.19 | |
18 Mo | 1.35±0.11 | 1.31±0.10 | 0.59 |
P value (baseline vs.18 mo) | 0.39 | 0.24 | |
CEA(ng/ml)
| |||
Baseline | 2.21±0.14 | 2.63±0.17 | 0.08 |
3 Days | 2.47±0.15 | 2.55±0.17 | 0.71 |
P value (baseline vs.3 d) | 0.03 | 0.48 | |
1 Mo | 2.33±0.14 | 2.76±0.19 | 0.11 |
P value (baseline vs.1 mo) | 0.33 | 0.40 | |
4 Mo | 2.37±0.15 | 2.42±0.15 | 0.91 |
P value (baseline vs.6 mo) | 0.25 | 0.21 | |
12 Mo | 2.33±0.18 | 2.44±0.16 | 0.62 |
P value (baseline vs.12 mo) | 0.58 | 0.34 | |
18 Mo | 2.22±0.16 | 2.55±0.24 | 0.16 |
P value (baseline vs.18 mo) | 0.21 | 0.34 | |
CRP(mg/L)
| |||
Baseline | 5.72±0.53 | 6.47±0.49 | 0.27 |
3 Days | 4.99±0.51 | 5.47±0.48 | 0.31 |
P value (baseline vs.3 d) | 0.12 | 0.06 | |
1 Mo | 3.70±0.40 | 3.54±0.31 | 0.80 |
P value (baseline vs.1 mo) | <0.0001 | <0.0001 | |
4 Mo | 3.20±0.33 | 3.34±0.30 | 0.54 |
P value (baseline vs.6 mo) | <0.0001 | <0.0001 | |
12 Mo | 3.04±0.19 | 3.00±0.29 | 0.46 |
P value (baseline vs.12 mo) | <0.0001 | <0.0001 | |
18 Mo | 3.56±0.43 | 3.42±0.38 | 0.76 |
P value (baseline vs.18 mo) | <0.0001 | <0.0001 | |
ALT(U/L)
| |||
Baseline | 30.5±1.8 | 32.8±2.1 | 0.41 |
3 Days | 31.6±2.1 | 32.9±2.7 | 0.85 |
P value (baseline vs.3 d) | 0.42 | 0.98 | |
1 Mo | 30.3±1.8 | 28.3±1.3 | 0.68 |
P value (baseline vs.1 mo) | 0.96 | 0.47 | |
4 Mo | 29.3±1.1 | 29.9±1.2 | 0.72 |
P value (baseline vs.6 mo) | 0.87 | 0.59 | |
12 Mo | 27.2±1.1 | 27.4±1.1 | 0.94 |
P value (baseline vs.12 mo) | 0.36 | 0.31 | |
18 Mo | 29.2±1.4 | 28.1±1.2 | 0.61 |
P value (baseline vs.18 mo) | 0.83 | 0.43 | |
TBIL(μmol/L)
| |||
Baseline | 16.7±1.5 | 15.1±1.3 | 0.63 |
3 Days | 11.6±0.6 | 11.5±0.5 | 0.89 |
P value (baseline vs.3 d) | 0.0003 | 0.006 | |
1 Mo | 15.1±0.7 | 13.8±0.6 | 0.32 |
P value (baseline vs.1 mo) | 0.32 | 0.31 | |
4 Mo | 14.5±1.0 | 16.0±1.1 | 0.27 |
P value (baseline vs.6 mo) | 0.22 | 0.60 | |
12 Mo | 14.2±0.7 | 15.6±0.5 | 0.12 |
P value (baseline vs.12 mo) | 0.14 | 0.76 | |
18 Mo | 14.6±0.7 | 13.4±0.6 | 0.36 |
P value (baseline vs.18 mo) | 0.31 | 0.28 | |
BUN(mmol/L)
| |||
Baseline | 5.30±0.18 | 5.63±0.22 | 0.28 |
3 Days | 4.91±0.19 | 5.19±0.17 | 0.12 |
P value (baseline vs.3 d) | 0.06 | 0.07 | |
1 Mo | 5.10±0.18 | 5.26±0.23 | 0.96 |
P value (baseline vs.1 mo) | 0.36 | 0.22 | |
4 Mo | 5.29±0.17 | 5.21±0.18 | 0.47 |
P value (baseline vs.6 mo) | 0.95 | 0.13 | |
12 Mo | 5.42±0.18 | 5.46±0.20 | 0.89 |
P value (baseline vs.12 mo) | 0.68 | 0.57 | |
18 Mo | 5.22±0.23 | 5.33±0.32 | 0.85 |
P value (baseline vs.18 mo) | 0.46 | 0.29 | |
CRE(μmol/L)
| |||
Baseline | 84.5±2.3 | 81.8±2.2 | 0.39 |
3 Days | 81.2±2.0 | 77.9±2.1 | 0.26 |
P value (baseline vs.3 d) | 0.14 | 0.14 | |
1 Mo | 78.5±2.4 | 76.3±2.0 | 0.46 |
P value (baseline vs.1 mo) | 0.06 | 0.07 | |
4 Mo | 83.5±2.2 | 78.2±2.0 | 0.07 |
P value (baseline vs.6 mo) | 0.71 | 0.17 | |
12 Mo | 84.0±2.0 | 80.4±1.8 | 0.19 |
P value (baseline vs.12 mo) | 0.84 | 0.63 | |
18 Mo | 82.6±2.1 | 79.7±2.7 | 0.48 |
P value (baseline vs.18 mo) | 0.56 | 0.61 |
Myocardial viability
Myocardial perfusion
Left ventricular function
Variable | Placebo (95 % CI) | WJMSCs(95 % CI) | P value |
---|---|---|---|
(number = 55) | (number = 57) | ||
Global LVEF (%)
| |||
Baseline | |||
Mean | 51.0±1.1(48.8~53.3) | 52.1±1.0(50.2~54.1) | 0.46 |
4 Months | |||
Mean | 54.2±0.9(52.5~56.1) | 58.5±0.7(57.1~60.0) | 0.0003 |
Difference | 3.2±0.9(1.4~5.0) | 6.4±0.7(4.9~7.9) | 0.008 |
P value (baseline vs.6 months) | 0.0009 | <0.0001 | |
12 Months | |||
Mean | 54.5±0.8(52.8~56.2) | 58.8±0.8(57.3~60.4) | 0.0002 |
Difference | 3.5±0.8(1.9~5.0) | 6.7±0.8(5.1~8.3) | 0.004 |
P value (baseline vs.12 months) | <0.0001 | <0.0001 | |
18 Months | |||
Mean | 54.0±0.8( 52.3~55.7) | 60.0±0.5 (58.9~61.0) | <0.0001 |
Difference | 2.8±1.2(0.4~5.1) | 7.8±0.9(6.0~9.7) | 0.001 |
P value (baseline vs.18 months) | 0.05 | <0.0001 | |
LVFS (%)
| |||
Baseline | |||
Mean | 26.6±0.7(25.2~27.9) | 27.3±0.6(26.0~28.6) | 0.42 |
4 Months | |||
Mean | 29.7±0.7(28.3~31.0) | 32.6±0.6(31.4~33.9) | 0.002 |
Difference | 3.1±0.6(1.9~4.3) | 5.3±0.6(4.0~6.6) | 0.01 |
P value (baseline vs.6 months) | <0.0001 | <0.0001 | |
12 Months | |||
Mean | 29.8±0.6(28.5~31.0) | 32.7±0.5(31.7~33.8) | 0.0005 |
Difference | 3.2±0.5(2.1~4.3) | 5.4±0.5(4.3~6.5) | 0.005 |
P value (baseline vs.12 months) | <0.0001 | <0.0001 | |
18 Months | |||
Mean | 28.6±0.6(20.8~35.6) | 33.6±0.5(27.3~39.1) | <0.0001 |
Difference | 2.1±0.8(−8.9~13.5) | 6.2±0.7(−4.1~16.4) | <0.0001 |
P value (baseline vs.18 months) | 0.01 | <0.0001 | |
WMSI (17-segment model)
| |||
Baseline | |||
Mean | 1.28±0.03(1.23~1.34) | 1.29±0.03(1.24~1.34) | 0.76 |
4 Months | |||
Mean | 1.16±0.02(1.11~1.21) | 1.10±0.01(1.07~1.12) | 0.02 |
Difference | −0.12±0.02(−0.16~−0.09) | −0.19±0.02(−0.23~−0.16) | 0.003 |
P value (baseline vs.6 months) | <0.0001 | <0.0001 | |
12 Months | |||
Mean | 1.15±0.02(1.11~1.20) | 1.09±0.02(1.06~1.12) | 0.02 |
Difference | −0.13±0.02( −0.17~−0.10) | −0.20±0.02(−0.23~−0.17) | 0.003 |
P value (baseline vs.12 months) | <0.0001 | <0.0001 | |
18 Months | |||
Mean | 1.16±0.9(1.02~1.40) | 1.07±0.01(1.00~1.17) | <0.0001 |
Difference | −0.13±0.02(−0.42~0.08) | −0.22±0.02(−0.57~0.04) | 0.01 |
P value (baseline vs.18 months) | <0.0001 | <0.0001 | |
End-systolic volume (ml)
| |||
Baseline | |||
Mean | 66.0±3.1(59.8~72.2) | 63.1±2.8(57.5~68.7) | 0.38 |
4 Months | |||
Mean | 63.4±2.8(57.7~69.0) | 55.9±2.1(51.7~60.2) | 0.07 |
Difference | −2.6±1.8(−6.4~1.1) | −7.2±1.9(−10.9~−3.5) | 0.09 |
P value (baseline vs.6 months) | 0.16 | 0.0003 | |
12 Months | |||
Mean | 62.5±2.8(56.9~68.0) | 55.1±2.1(50.9~59.4) | 0.06 |
Difference | −3.5±1.9(−7.3~0.2) | −8.0±2.0(−12.1~−3.9) | 0.12 |
P value (baseline vs.12 months) | 0.11 | 0.0002 | |
18 Months | |||
Mean | 62.8±0.9(59.1~66.6) | 49.2±1.0(47.1~51.2) | <0.0001 |
Difference | −2. 9±2.1(−7.1~1.3) | −14.0±2.2(−18.4~−9.5) | 0.0004 |
P value (baseline vs.18 months) | 0.2 | <0.0001 | |
End-diastolic volume (ml)
| |||
Baseline | |||
Mean | 132.2±3.9(124.3~140.0) | 130.3±3.8(122.7~137.9) | 0.49 |
4 Months | |||
Mean | 136.0±4.0(127.9~144.0) | 133.2±3.2(126.8~139.5) | 0.72 |
Difference | 3.8±2.3(−0.7~8.4) | 2.9±2.6(−2.3~8.0) | 0.78 |
P value (baseline vs.6 months) | 0.20 | 0.07 | |
12 Months | |||
Mean | 134.5±3.9(126.6~142.4) | 131.9±3.1(125.8~138.1) | 0.60 |
Difference | 2.4±2.5(−2.6~7.3) | 1.6±2.8(−4.0~7.2) | 0.84 |
P value (baseline vs.12 months) | 0.45 | 0.22 | |
18 Months | |||
Mean | 136.4±3.1(130.1~142.7) | 122.7±1.6 (119.5~125.8) | 0.0001 |
Difference | 4.1±2.4(−0.8~9.0) | −7.6±3.13(−13.9~−1.4) | 0.004 |
P value (baseline vs.18 months) | 0.1 | <0.0001 |